Although Fabry disease is relatively rare, it is important not to miss the diagnosis as enzyme replacement therapy or, more recently, oral pharmacological chaperone therapy (Migalastat) for specific mutant forms of GLA (18), are available in Australia through the Life Saving Drugs Program, a fully subsidized program for life threatening and rare diseases (19). This evidence concerns the gene GLA and Fabry disease.